Page last updated: 2024-08-21

thiazoles and s 1033

thiazoles has been researched along with s 1033 in 316 studies

Research

Studies (316)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	104 (32.91)	29.6817
2010's	211 (66.77)	24.3611
2020's	1 (0.32)	2.80

Authors

Authors	Studies
Cowan-Jacob, SW; Deininger, MW; Druker, BJ; Heinrich, MC; Jia, T; Lee, FY; Manley, PW; Mestan, J; O'Hare, T; Stoffregen, EP; Walters, DK	1
D'Antonio, J	1
Shah, NP	1
Corbin, AS; Druker, BJ; O'Hare, T	1
Hampton, T	1
Ohnishi, K	2
Cortes, J; Quintás-Cardama, A	3
Bradeen, HA; Deininger, MW; Druker, BJ; Eide, CA; Johnson, KJ; Lee, FY; O'Hare, T; Willis, SG	1
Druker, BJ	1
Fricker, J	1
Cortes, J; Giles, F; Jones, D; Kantarjian, H; Nicaise, C; O'Brien, S; Quintas-Cardama, A; Talpaz, M	1
Chen, XG; Liu, H	1
Czyz, M; Jakubowska, J	1
Cortes, J; Giles, F; Jabbour, E; Kantarjian, H; O'Brien, S	1
Maekawa, T	1
Kimura, S	5
Heaney, NB; Holyoake, TL	1
von Mehren, M	1
Ohyashiki, K; Tauchi, T	1
Andersson, BS; Champlin, R; Cortes, J; de Lima, M; Giles, F; Giralt, S; Jabbour, E; Kantarjian, H; Kebriaei, P; Shpall, E	1
Schiffer, CA	1
Oestreicher, P	1
Agaram, NP; Antonescu, CR; Besmer, P; Clarkson, BD; D'Adamo, D; DeMatteo, RP; Guo, T; Hom, G; Maki, RG; Schwartz, GK; Singer, S; Veach, D; Wong, GC	1
Martinelli, G; Paolini, S; Piccaluga, PP	1
Bennett, KL; Colinge, J; Dürnberger, G; Fernbach, NV; Hantschel, O; Kaupe, I; Köcher, T; Planyavsky, M; Remsing Rix, LL; Rix, U; Superti-Furga, G; Valent, P	1
Alimena, G; Breccia, M; Cannella, L; Nanni, M; Stefanizzi, C	1
Thomas, X	1
Brandwein, J	1
Kujawski, L; Talpaz, M	1
Ashihara, E; Deguchi, Y; Fujiyama, Y; Hodohara, K; Kimura, S; Maekawa, T; Niwa, T	1
Bui, B; Italiano, A	1
Alimena, G; Breccia, M; Cannella, L; Frustaci, A; Muscaritoli, M; Stefanizzi, C	1
Akhmetshina, A; Axmann, R; Dees, C; Distler, JH; Distler, O; Gay, S; Jüngel, A; Maurer, B; Pileckyte, M; Schett, G; Zwerina, J	1
Buchanan, S; Burley, SK; Corbin, AS; Deininger, MW; Eide, CA; Holme, K; Jessen, KA; Lewis, HA; O'Hare, T; Romero, RD; Tang, C; Tyner, JW; Wong, MJ	1
Cortes, J; Kantarjian, H	2
Hantschel, O; Rix, U; Superti-Furga, G	1
Cools, J; Cortes, J; Garcia-Manero, G; Gilliland, DG; Kantarjian, H; Lee, F; Lennon, PA; Manshouri, T; Quintás-Cardama, A; Tong, W; Vega, F	1
Cowan-Jacob, SW; Fendrich, G; Grzesiek, S; Jahnke, W; Manley, PW; Strauss, A; Vajpai, N	1
Barańska, M; Gniot, M; Iwoła, M; Komarnicki, M; Lewandowska, M; Lewandowski, K	1
DiPersio, JF; Ramirez, P	1
Borthakur, G; Cortes, J; Garcia-Manero, G; Kantarjian, H; O'Brien, S; Ravandi, F; Shan, J; Tam, CS	1
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A	1
Deininger, MW	1
Arnold, R; Guilhot, F; Koren-Michowitz, M; le Coutre, P; Leiba, M; Martineau, G; Nagler, A; Renaud, M; Ribakovski, E; Schleuning, M; Shimoni, A	1
Distler, JH; Distler, O	1
Wang, ES; Wetzler, M; Zeidan, A	1
Kubuki, Y	1
Hohl, RJ; Holstein, SA; Stokes, JB	1
Bewry, NN; Boulware, D; Emmons, MF; Hazlehurst, LA; Nair, RR; Pinilla-Ibarz, J	1
Alnadaf, T; Buchdunger, E; Day, E; Jarai, G; Manley, PW; Spiegel, K; Walker, C; Waters, B	1
Belanger, C; Belloc, F; Etienne, G; Hayette, S; Lagarde, V; Leroy, C; Mahon, FX; Manley, PW; Nicolini, F; Pasquet, JM; Roche, S; Turcq, B	1
Boschelli, F; Gambacorti-Passerini, C; Magistroni, V; Marega, M; Perini, P; Piazza, R; Redaelli, S; Rostagno, R	1
Gora-Tybor, J; Robak, T	1
Cervantes, F	1
Müller, BA	1
Cortes, JE; Jabbour, E; Kantarjian, HM	1
Kantarjian, H	1
Hantschel, O; Kuriyan, J; Superti-Furga, G; Winger, JA	1
Cortés, JE; Kantarjian, H; Quintás-Cardama, A	1
Bixby, DL; Talpaz, M	1
Cortes, J; Fava, C; Kantarjian, H; Verma, D	1
Borthakur, G; Cortes, J; Fava, C; Garcia-Manero, G; Jabbour, E; Jain, N; Kantarjian, HM; O'Brien, S; Ravandi, F; Rios, MB; Shan, J; Verstovsek, S	1
Cortes, JE; Kantarjian, H; Pavlovsky, C	1
Mauro, MJ	4
McFarland, KL; Wetzstein, GA	1
Duncan, C; Galviz, G; Hsieh, Y; Zhou, Q	1
Cortes, J; Jabbour, E; Kantarjian, H	3
Giles, FJ	2
Bellodi, C; Calabretta, B; Dinsdale, D; Donato, N; Dyer, MJ; Galavotti, S; Hamilton, A; Helgason, GV; Holyoake, T; Hunter, A; Lidonnici, MR; Nicotera, P; Ronchetti, M; Salomoni, P; Selmi, T; Soliera, AR; Tirrò, E; Van Etten, RA; Vigneri, P; Yacobi, R; Young, KW	1
Alimena, G; Breccia, M; Cannella, L; Napoleone, L; Santopietro, M; Stefanizzi, C	1
Giles, FJ; Kelly, K; Mahalingam, D; Padmanabhan, S; Swords, R	1
Bilban, M; Burkard, TR; Colinge, J; Gstoettenbauer, A; Hantschel, O; Kaupe, I; Superti-Furga, G; Valent, P	1
Baietto, L; D'Avolio, A; De Francia, S; De Martino, F; Di Carlo, F; Di Perri, G; Pirro, E; Racca, S; Saglio, G; Siccardi, M; Simiele, M	1
Alimena, G; Baccarani, M; Breccia, M; Castagnetti, F; Colaci, E; Foà, R; Iori, AP; Latagliata, R; Martinelli, G; Palandri, F; Rosti, G; Torelli, GF; Usai, S; Valle, V	1
Storey, S	1
Baumgartner, C; Gleixner, KV; Gruze, A; Hadzijusufovic, E; Peter, B; Pickl, WF; Rebuzzi, L; Thaiwong, T; Valent, P; Willmann, M; Yuzbasiyan-Gurkan, V	1
Borthakur, G; Burger, JA; Cortes, J; Jabbour, E; Jones, D; Kantarjian, HM; Koller, C; O'Brien, S; Tam, C; Wierda, WG	1
Abruzzese, E; Amabile, M; Baccarani, M; Castagnetti, F; Cilloni, D; Colarossi, S; de Matteis, S; Gnani, A; Gozzini, A; Gugliotta, G; Iacobucci, I; Martinelli, G; Merante, S; Orlandi, E; Palandri, F; Paolini, S; Papayannidis, C; Poerio, A; Rosti, G; Soverini, S	1
Asenova, S; Ayuk, F; Bacher, U; Brummendorf, TH; Klyuchnikov, E; Kröger, N; Ocheni, S; Osanmaz, O; Schafhausen, P; Zabelina, T; Zander, AR	1
Ernst, T; Gruber, FX; Hochhaus, A; Lange, T; Maier, J; Mikkola, I; Müller, MC; Niederwieser, D; Pelz-Ackermann, O; Pfirrmann, M; Porkka, K	1
Jabbour, E; Soverini, S	1
Adrian, LT; Deininger, MW; Druker, BJ; Eide, CA; Lange, T; O'Hare, T; Snead, JL	1
Cortes, J; Estrov, Z; Faderl, S; Garg, RJ; Kantarjian, H; O'Brien, S; Quintás-Cardama, A	1
Gelderblom, H; Guchelaar, HJ; van Erp, NP	1
Bruccoleri, RE; Cao, J; Cockett, MI; de Silva, H; He, A; Huang, W; Ji, RR; Jin, Y; Kayne, PS; Neubauer, MG; Neuhaus, IM; Ott, KH; Penhallow, B; Ross-Macdonald, P; Siemers, NO	1
Goh, HG; Kim, D; Kim, DW; Kim, SH; Kim, WS; Kweon, IY; Lee, J; Park, SH	1
Cortés, JE; Jabbour, E; Kantarjian, H	1
Apáti, A; Hegedus, C; Katona, M; Kéri, G; Magócsi, M; Német, K; Orfi, L; Ozvegy-Laczka, C; Sarkadi, B; Szakács, G; Takáts, Z; Váradi, A	1
Cortes, J; Hochhaus, A; Jabbour, E; Kantarjian, HM; La Rosée, P	1
Chan, YY; Kwan, TK; Lie, AK; Liu, HS; Ma, ES; Sim, JP; Wan, TS; Yeung, YM; Yip, SF	1
Apperley, JF; Bua, M; de Lavallade, H; Drummond, MW; Foroni, L; Goldman, JM; Holyoake, TL; Khorashad, JS; Marin, D; Milojkovic, D; Nicholson, E; Paliompeis, C; Reid, A; Rezvani, K; Shepherd, P; Szydlo, R	1
Ashby, CR; Chen, A; Chen, X; Chen, ZS; Hopper-Borge, E; Kuang, YH; Lei, Y; Ouyang, J; Shen, T; Tiwari, AK; Zhou, Y	1
Tojo, A	2
Hamerschlak, N; Kerbauy, FR; Mac-Donald Bley do Nascimento, C; Mauro Kutner, J; Ribeiro, AA; Rodrigues, M; Santos, FP	1
Branford, S; Hughes, TP; Melo, JV	1
Apperley, J; Baccarani, M; Cervantes, F; Cortes, J; Deininger, M; Goldman, J; Gratwohl, A; Guilhot, F; Hehlmann, R; Hochhaus, A; Horowitz, M; Hughes, T; Kantarjian, H; Larson, R; Niederwieser, D; Pane, F; Radich, J; Saglio, G; Silver, RT; Simonsson, B	1
Matsunaga, T	1
Chang, MS; Haferlach, C; Haferlach, T; Hofmann, WK; Kang, S; Kato, M; Kawamata, N; Kim, HS; Koeffler, HP; Kohlmann, A; Meixel, A; Mossner, M; Müschen, M; Nowak, D; Nowak, V; Ogawa, S; Paquette, R; Thoenissen, NH; Thoennissen, NH; Weiss, T	1
Stock, W	1
Hiwase, DK; Hughes, TP; Melo, JV; Saunders, V; White, D; Zrim, S	1
Ravandi, F; Santos, FP	1
Azam, M; Clackson, T; Daley, GQ; Dalgarno, D; Einhorn, W; Huang, WS; Powers, JT; Sawyer, TK; Shakespeare, WC; Zhu, X	1
Attar, EC; DeAngelo, DJ	1
Ernst, T; Gruber, FX; Hochhaus, A; Kiselev, Y; Mikkola, I	1
Cortes, J; Hochhaus, A; Kantarjian, HM; La Rosée, P	1
Grünebach, F; Hilpert, J; Krusch, M; Placke, T; Salih, HR; Salih, J; Steinle, A	1
Akiyama, H; Fukuda, S; Kobayashi, T; Nagata, Y; Ohashi, K; Sakamaki, H; Yamashita, T	1
Baccarani, M; Castagnetti, F; Gugliotta, G; Martinelli, G; Palandri, F; Rosti, G	1
Antolino, A; Consoli, C; Consoli, ML; Cupri, A; Del Fabro, V; Di Raimondo, F; Massimino, M; Stagno, F; Stella, S; Tambè, L; Vigneri, P	1
Ahluwalia, MS; Battiwalla, M; Cohen, IL; Francis, J; McCarthy, PL; Paplham, P; Smiley, S; Spangenthal, E; Wang, E; Wetzler, M	1
Beyer, C; Distler, JH; Distler, O	1
Ambudkar, SV; Bates, SE; Brendel, C; Deeken, JF; Dohse, M; Neubauer, A; Robey, RW; Scharenberg, C; Shukla, S; Volkmann, T	1
Schiffer, CA; Zonder, JA	1
Alvarado, Y; Cortes, J; Giles, FJ; Swords, R	1
Bonvalot, S; Cioffi, A; Dômont, J; Le Cesne, A; Tardieu, M	1
Borthakur, G; Cortes, J; Estrov, Z; Garcia-Manero, G; Kantarjian, H; Koller, C; O'Brien, S; Shan, J; Verma, D	1
Baccarani, M; Saglio, G	1
Abruzzese, E; Baccarani, M; Bhatia, R; Bosly, A; Cortes, J; Dünzinger, U; Facon, T; Fischer, T; Gallagher, NJ; Giles, FJ; Goldberg, S; Jagasia, M; Kam, GL; Kantarjian, HM; Kim, DW; Larson, RA; Mahon, FX; Marin, D; Mendrek, W; Mueller, MC; Rosti, G; Shou, Y	1
Sawyers, CL	1
Cortes, J; Fava, C; Garcia-Manero, G; Kantarjian, H; O'Brien, S; Ravandi, F; Santos, FP; Shan, J; Thomas, D; Wierda, W	1
Valent, P	1
Smith, BD; Stein, B	1
Buclin, T; Decosterd, LA; Duchosal, MA; Haouala, A; Montemurro, M; Widmer, N	1
Apperley, JF; Bua, M; Dazzi, F; de Lavallade, H; Foroni, L; Goldman, JM; Ibrahim, AR; Khorashad, JS; Marin, D; Milojkovic, D; Paliompeis, C; Reid, A; Rezvani, K; Szydlo, R	1
Apperley, JF; Clark, RE; Daghistani, M; De Melo, VA; Foroni, L; Gerrard, G; Goldman, JM; Khorashad, JS; Marin, D; May, PC; Milojkovic, D; Paliompeis, C; Reid, AG; Wang, L	1
Deininger, M; Hochhaus, A; Jabbour, E	1
Breccia, M	1
Cortes, J; Mauro, MJ; Pinilla-Ibarz, J	1
Arnold, R; Braun, D; Dörken, B; Grille, P; Kim, TD; le Coutre, P; Nogai, H; Plöckinger, U; Schwarz, M; Schweizer, U; Westermann, J	1
Hassan, AQ; Sharma, SV; Warmuth, M	1
Gong, Y; Liu, T; Meng, W; Xing, H	1
Bencivenga, D; Borriello, A; Caldarelli, I; Cucciolla, V; Danise, P; Della Ragione, F; Oliva, A; Perrotta, S; Ronzoni, L; Usala, E	1
Akard, LP	1
Porkka, K; Richter, J; Simonsson, B	1
Beyazit, Y; Haznedaroglu, IC; Kekilli, M	1
Borthakur, G; Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Rios, MB; Shan, J; Wierda, W	1
Bollu, VK; Griffin, JD; Guerin, A; Guo, A; Wu, EQ; Yu, AP	1
Camitta, B; Prestidge, T; Schultz, KR	1
Clackson, T; Deininger, MW; Druker, BJ; Eide, CA; O'Hare, T	1
Etienne, G; Huguet, F	1
Liu, D; Rafiyath, S; Wei, G	1
Ernst, T; Hanfstein, B; Hehlmann, R; Hochhaus, A; Kreil, S; Leitner, A; Lorentz, C; Müller, MC; Schenk, T; Schwindel, U	1
Cortés, JE; Holyoake, T; Kantarjian, H; Ranganathan, A; Saglio, G	1
Cross, NC; Ernst, T; Hochhaus, A; La Rosée, P; Müller, MC	1
Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N	1
Okimoto, RA; Van Etten, RA	1
Burchert, A; Neubauer, A	1
Engen, JR; Gray, NS; Iacob, RE; Zhang, J	1
Chen, Y; Li, D; Li, S; Peng, C	1
Baccarani, M; Cortes, JE; Jabbour, E; Kantarjian, HM; Saglio, G	1
Quintás-Cardama, A; Santos, FP	1
Alimena, G; Breccia, M	3
Harnicar, S	1
Branford, S; Prime, J	1
Hughes, TP; White, DL	1
Gaultney, JG; Janssen, JJ; Redekop, WK; Sanhueza, E; Uyl-de Groot, CA	1
Silver, RT	1
Craddock, C; Novitzky-Basso, I	1
Abruzzo, LV; Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Quintás-Cardama, A; Shan, J; Verstovsek, S	1
Betts, KA; Bollu, VK; DeAngelo, DJ; Guo, A; Kantor, E; Parikh, K; Signorovitch, JE; Wei, LJ; Williams, D; Wu, EQ	1
Ravandi, F	1
Geoerger, B; Leblond, P	1
Baccarani, M; Iacobucci, I; Martinelli, G; Rosti, G; Soverini, S	1
Akin, C; DeRemer, DL; Ustun, C	1
Hiwase, DK; White, DL; Yeung, DT	1
Blay, JY; Chaigneau, L; Curtit, E; Dobi, E; Kalbacher, E; Mansi, L; Nguyen, T; Pivot, X; Viel, E	1
Radich, JP	1
Hughes, TP; Moore, S; Parker, WT; Prime, JA; Schafranek, L; Tang, C; Watkins, DB; White, DL	1
Borthakur, G; Cortes, J; Faderl, S; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; O'Brien, S; Ravandi, F; Shan, J	1
Ohyashiki, K; Okabe, S; Tanaka, Y; Tauchi, T	1
Demarquet, M; Labussière-Wallet, H; Nicolas-Virelizier, E; Nicolini, FE	1
Engh, RA; Ernst, T; Gruber, FX; Hochhaus, A; Lange, T; Maier, J; Mikkola, I; Porkka, K	1
Brossart, P; Grünebach, F; Gutknecht, M; Rittig, SM; Salih, HR; Salih, J; Schwarzbich, MA	1
Guilhot, F; Roy, L; Tomowiak, C	1
Bassan, R; Bussini, A; Castagnetti, F; Gnani, A; Intermesoli, T; Rosti, G; Soverini, S; Spinelli, O	1
Matsumura, I	2
Branford, S; Ho, M; Hughes, TP; Irwin, DL; Lawrence, RM; Parker, WT; Scott, HS	1
Ariaudo, A; Baietto, L; Cusato, J; D'Avolio, A; De Francia, S; Di Carlo, F; Di Perri, G; Fava, C; Saglio, G; Simiele, M	1
Kim, EJ; Zalupski, MM	1
Krusch, M; Salih, HR	1
Erben, P; Hanfstein, B; Härtel, N; Hochhaus, A; Klag, T; La Rosée, P; Mueller, MC; Schenk, T	1
Bhatia, R; Chen, WY; Roth, M; Wang, Z; Yuan, H; Zhang, H	1
Kalaycio, M; Tiu, R	1
Reed, SD	1
Hoyle, M; Liu, Z; Moxham, T; Rogers, G; Stein, K	1
Cziraky, M; Davis, C; Hamdan, M; Hirji, I; Oliveria, SA; Yood, MU	1
Aoki, J; Hirashima, Y; Kakihana, K; Kobayashi, T; Ohashi, K; Sakamaki, H	1
Druker, BJ; Eide, CA; Hayward, R; Heidorn, S; Marais, R; Niculescu-Duvaz, I; O'Hare, T; Packer, LM; Rana, S; Rebocho, A; Springer, C; Zabriskie, MS	1
Giannopoulos, K; Kosior, K; Lewandowska-Grygiel, M	1
Apperley, JF; Bua, M; Foroni, L; Gerrard, G; Goldman, J; Ibrahim, AR; Marin, D; Milojkovic, D; Reid, A; Rezvani, K; Szydlo, R	1
Balci, TB; Karakus, S; Ozdogu, H; Sahin, FI	1
Branford, S; Ho, M; Hughes, TP; Parker, WT; Scott, HS	1
Hagihara, K; Hayashi, Y; Hino, M; Hirose, A; Katayama, T; Koh, H; Nakamae, H; Nakamae, M; Nakane, T; Nakao, Y; Terada, Y	1
Erba, HP; Pham, DC; Tai, S; Vu, H; Zaiden, R	1
Cortes, J; Jabbour, E; Kantarjian, H; O'Brien, S; Pemmaraju, N; Quintas-Cardama, A; Ravandi, F; Shan, J; Verstovsek, S; Wierda, W	1
Dreosti, L; Jogessar, V; Louw, VJ; Moodley, D; Novitzky, N; Patel, M; Ruff, P; Schmidt, A; Willem, P	1
Baccarani, M; Besson, N; Brümmendorf, TH; Cortes, JE; Countouriotis, A; Gambacorti-Passerini, C; Kantarjian, HM; Kelly, V; Khoury, HJ; Kim, DW; Leip, E; Zaritskey, A	1
Fukushima, N; Ichinohe, T; Kimura, S	1
Goulden, S; Stevens, A; Sutcliffe, F	1
Pfirrmann, M; Saussele, S	1
Wise, J	1
Atallah, E; Haddad, RY; Torgerson, SR	1
Bergeron, A; Bergot, E; Bourdin, A; Bouvaist, H; Canuet, M; Girerd, B; Guignabert, C; Günther, S; Humbert, M; Jaïs, X; Macro, M; Montani, D; Natali, D; O'Callaghan, DS; Perros, F; Pison, C; Poubeau, P; Savale, L; Simonneau, G; Sitbon, O; Tubert-Bitter, P; Zalcman, G	1
Candrilli, SD; Iyer, S; Kaye, JA; Mitra, D; Trask, PC	1
Boxer, SG; Levinson, NM	1
Di Raimondo, F; Stagno, F; Vigneri, P	1
Koskela, H; Koskenvesa, P; Mustjoki, S; Porkka, K	1
Jootar, S	1
Berghausen, EM; Brandes, RP; Butrous, E; Butrous, G; Dabral, S; Dahal, BK; Ghofrani, HA; Grimminger, F; Pullamsetti, SS; Rosenkranz, S; Savai, R; Schermuly, RT; Seeger, W; Tretyn, A; Weissmann, N	1
Giles, F; Gjertsen, B; Labar, B; Mahon, FX; Rosti, G; Swords, R; Turkina, A	1
Hoyle, M; Liu, Z; Moxham, T; Pitt, M; Rogers, G; Stein, K; Thompson Coon, J	1
Granot, G; Lahav, M; Mor-Tzuntz, R; Raanani, P; Shapira, S; Shpilberg, O; Uziel, O	1
Bryant, J; Clegg, A; Colquitt, JL; Cooper, K; Frampton, GK; Loveman, E	1
Cervantes, F; le Coutre, P; Porkka, K; Saglio, G; Steegmann, JL	1
Chen, L; Griffin, JD; Guérin, A; Ponce de Leon, D; Wu, EQ	1
Abruzzese, E; Albano, F; Alimena, G; Annunziata, M; Breccia, M; Castagnetti, F; Cavazzini, F; Fava, C; Gozzini, A; Luciano, L; Martino, B; Musto, P; Pregno, P; Rosti, G; Russo Rossi, A; Sgherza, N; Specchia, G; Stagno, F; Tiribelli, M; Visani, G	1
Fava, C; Rege-Cambrin, G; Saglio, G	1
Dingermann, T; Marschalek, R; Zündorf, I	1
Kralj, E; Kristl, A; Pajič, T; Trontelj, J	1
Balakrishnar, B; Clements, A; Gao, B; Gurney, H; Wong, M; Yeap, S	1
Azam, M	1
Jabbour, E; Mathisen, MS; O'Brien, S	1
Bowles, DW; Green, K; Thienelt, CD	1
Cross, M; Ernst, T; Gruber, FX; Hochhaus, A; Lange, T; Maier, J; Müller, MC; Niederwieser, D; Pfirrmann, M	1
Jabbour, E; Kantarjian, H	1
Hirase, C; Matsumura, I	1
Anderson, R; Ciani, O; Cooper, C; Crathorne, L; Garside, R; Hoyle, M; Jones-Hughes, T; Osipenko, L; Pavey, T; Rudin, C; Ukoumunne, O; Venkatachalam, M	1
Jacobsen, PB; Jim, HS; Komrokji, R; Lancet, J; Lee, MR; Phillips, KM; Pinilla-Ibarz, J; Small, BJ; Sokol, L; Sotomayor, E; Sweet, K; Tinsley, S	1
Marin, D	1
Amitay-Laish, I; Berman, E; Busam, KJ; Drucker, AM; Lacouture, ME; Wu, S	1
Baxendale, IR; Deadman, BJ; Hopkin, MD; Ley, SV	1
Kamel-Reid, S; Kim, DD; Lee, H; Lipton, JH	1
Jabbour, EJ; Quintás-Cardama, A	1
Noronha, S; Sawyer, S	1
Aung, T; Beutler, M; Cameron, S; Chapuy, B; Haase, D; Hupfeld, T; Koch, R; Larosee, P; Schrader, V; Truemper, L; Veltkamp, C; Wulf, GG	1
Boqué, C; Cabezón, M; Feliu, E; Fernández de Sevilla, A; Fernández, C; Grau, J; Marcé, S; Millá, F; Navarro, JT; Ribera, JM; Xicoy, B; Zamora, L	1
Costantini, A; Lasala, R; Rizzo, RC; Santoleri, F; Sorice, P	1
Antonescu, CR; Jain, S; Martz, J; Mosquera, JM; Popa, EC; Qin, L; Vahdat, LT	1
Gómez Casares, MT; León, LG	1
Chen, L; Griffin, JD; Guerin, A; Ionescu-Ittu, R; Luo, J; Macalalad, AR; Wu, EQ	1
Irvine, E; Williams, C	1
Andriamanana, I; Duretz, B; Gana, I; Hulin, A	1
Robert, C; Sibaud, V	1
Borroni, G; Brazzelli, V; Grasso, V	1
Carrascosa, R; Fraga, J; García Diez, A; Llamas-Velasco, M; Requena, L; Steegmann, JL	1
Borthakur, G; Cardenas-Turanzas, M; Cortes, J; Jabbour, E; Jain, P; Kantarjian, H; Nazha, A; O'Brien, S; Pierce, S; Quintás-Cardama, A; Ravandi, F; Romo, CG; Verstovsek, S	1
Onoda, M; Shono, K; Togasaki-Yoshimoto, E; Yokota, A	1
Aguzzi, C; Boccadoro, M; Cerrano, M; Crisà, E; Ferrero, D; Pregno, P; Riccomagno, P	1
Apperley, JF; Baccarani, M; Cervantes, F; Clark, RE; Cortes, JE; Deininger, MW; Goldman, JM; Guilhot, F; Hehlmann, R; Hjorth-Hansen, H; Hochhaus, A; Hughes, TP; Kantarjian, HM; Kim, DW; Larson, RA; Lipton, JH; Mahon, FX; Martinelli, G; Mayer, J; Müller, MC; Niederwieser, D; Pane, F; Radich, JP; Rosti, G; Rousselot, P; Saglio, G; Saußele, S; Schiffer, C; Silver, R; Simonsson, B; Soverini, S; Steegmann, JL	1
Chen, LT; Chen, TS; Chiang, NJ; Hsueh, YS; Ko, CH; Li, CF; Lin, CL; Shan, YS; Shih, NY; Wang, LM; Yen, CC	1
Klamová, H	1
Borthakur, G; Burger, JA; Cortes, JE; Falchi, L; Garcia-Manero, G; Jabbour, EJ; Kantarjian, HM; Luthra, R; O'Brien, S; Quintás-Cardama, A; Ravandi-Kashani, F; Verma, D; Verstovsek, S; Wang, X	1
Saglio, G; Savona, MR	1
Auger, N; Bennaceur-Griscelli, A; Bourhis, JH; Castaigne, S; de Botton, S; Ghez, D; Ianotto, JC; Micol, JB; Pasquier, F; Rigaudeau, S; Rousselot, P; Saada, V; Spentchian, M; Terré, C	1
Clark, R; Drummond, M; Gallipoli, P; Heaney, N; Holyoake, TL; Hughes, T; McLintock, L; Michor, F; Nicolini, FE; Paul, J; Stobo, J; Tighe, J; Wilson, G	1
Bergot, E; Godinas, L; Guignabert, C; Humbert, M; Montani, D; Perros, F; Seferian, A; Sibille, Y	1
Abruzzese, E; Breccia, M; Latagliata, R	1
Druker, BJ; Eide, CA; O'Hare, T; Shukron, O; Vainstein, V	1
Miura, M; Takahashi, N	1
Gastl, G; Kastner, U; Lion, T; Mitterbauer-Hohendanner, G; Seger, C; Webersinke, G	1
Jabbour, E; Lipton, JH	1
Eadie, LN; Hughes, TP; White, DL	1
Ayyagari, R; Chen, L; Reichmann, WM; Signorovitch, J; Wu, EQ	1
Bertomeu, T; Bucur, O; Dewar, R; Goganau, I; Khosravi-Far, R; Pennarun, B; Petrescu, SM; Stancu, AL	1
Ando, T; Kimura, S; Kojima, K	1
Dehesa, L; Kerdel, F; Nuno-Gonzalez, A; Ricotti, C	1
Hughes, T; White, D	1
Boiso Moreno, S; Carlsson, B; Gréen, H; Jönsson, JI; Skoglund, K; Vikingsson, S	1
Abruzzo, L; Alattar, ML; Borthakur, G; Champlin, R; Cortes, JE; Ferrajoli, A; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, HM; Luthra, R; O'Brien, S; Ohanian, M; Pierce, S; Quintas-Cardama, A; Ravandi, F; Trinh, LX; Verstovsek, S	1
Adams, E; Chen, H; Chopra, S; Van Schepdael, A; Wang, X	1
Ikezoe, T; Nishioka, C; Nobumoto, A; Tsuda, M; Yang, J; Yokoyama, A	1
Inokuchi, K; Nakayama, K	1
Anderson, KR; Chambers, CR; Cusano, F; Lam, N; Savoie, ML; Sheikh, N; Yau, PS	1
Baldus, CD; Bock, J; Hofmann, WK; Kühl, AA; Mochmann, LH; Neumann, M; Nowak, V; Ortiz-Tanchez, J; von der Heide, EK	1
Akin, C; Bindslev-Jensen, C; Broesby-Olsen, S; Maurer, M; Siebenhaar, F	1
Beaune, P; de Waziers, I; Favre, A; Figg, WD; Kiehl, P; McMullen, J; Montemurro, M; Narjoz, C; Rochat, B	1
Brazzelli, V; Croci, G; Grasso, V; Vassallo, C	1
Ahmad, S; Anderson, DJ; Arpin, CC; Baron, R; Deininger, MW; Eiring, AM; Engar, AJ; Gunning, PT; Heaton, WL; Khorashad, JS; Kraft, IL; Mason, CC; Moriggl, R; O'Hare, T; Page, BDG; Pomicter, AD; Resetca, D; Reynolds, KR; Senina, A; Tantravahi, SK; Todic, A; Vellore, NA; Wilson, DJ; Zabriskie, MS; Zhang, TY	1
Fukushima, N; Hayashi, S; Kimura, S; Kojima, K; Sueoka, E; Tomimasu, R; Yoshimura, M	1
Branford, S; Cortes, J; Gonen, M; Hughes, T; Michor, F; Olshen, A; Quintás-Cardama, A; Tang, M	1
Darkow, T; Landsman-Blumberg, P; McMorrow, D; Mullins, CD; Smith, D; Trivedi, D	1
Takahashi, N	1
Betts, KA; Chen, L; DeAngelo, DJ; Galebach, P; Reichmann, WM; Signorovitch, JE; Thomason, D; Wu, EQ	1
Gambacorti-Passerini, C; Piazza, R	1
Blalock, SJ; Earnshaw, SR; Fang, G; Happe, LE; Richards, KL; Walko, CM; Ward, MA	1
Candrilli, SD; Iyer, S; Kaye, JA; Whiteley, J	1
Cortes, J; Malhotra, R; Mauro, M; Saglio, G; Steegmann, JL; Ukropec, JA; Wallis, NT	1
Bennuru, S; Dolan, MA; Nutman, TB; O'Connell, EM; Steel, C	1
Alimena, G; Breccia, M; Colafigli, G; Diverio, D; Latagliata, R; Mancini, M; Molica, M; Tafuri, A	1
Alvarez-Larrán, A; Bautista, G; Bobillo, S; Boqué, C; Cuevas, B; de Las Heras, N; Deben, G; Fernandez, A; García Garay, Mdel C; García-Gutiérrez, V; Giraldo, P; Guinea, JM; Iglesias Pérez, A; Lopez Lorenzo, JL; Maestro, B; Martin Mateos, ML; Martinez-Trillos, A; Mata, I; Ortega, F; Portero, A; Ramirez Sánchez, MJ; Romero, E; Romo Collado, A; Ruiz, C; Sebrango, A; Steegmann, JL; Tallón, J; Valencia, S	1
Lee, CS; Liu, TC; Wang, HC	1
Eigendorff, E; Ernst, T; Hochhaus, A; La Rosée, P	1
Nishida, T; Tsukazaki, K	1
Dahl, J; Jabbour, EJ; Mace, ML	1
Capitani, S; Celeghini, C; Evangelisti, C; Marisi, G; Martelli, AM; McCubrey, JA; Neri, LM; Simioni, C; Ulivi, P; Ultimo, S; Zauli, G	1
Bakhshi, S; Pushpam, D	1
Cantonetti, M; Cattel, F; Celeste, MG; Colasanto, I; Costantini, A; de Rosa, C; Di Biagio, K; Federici, F; Franceschini, L; Frazzetto, A; La Barba, G; Lanzillo, R; Luciano, L; Monteverde, M; Musicco, F; Pane, F; Pasquazi, A; Ranucci, E; Rizzo, M; Rossi, C; Santoleri, F; Scaldaferri, M; Scortechini, AR; Torquati, G; Vozza, A	1

Reviews

132 review(s) available for thiazoles and s 1033

Article	Year
Chronic myelogenous leukemia. Clinical journal of oncology nursing, 2005, Volume: 9, Issue:5 Topics: Age Distribution; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Mutation; Nurse's Role; Oncology Nursing; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Stem Cell Transplantation; Thiazoles; Translocation, Genetic	2005
Targeted CML therapy: controlling drug resistance, seeking cure. Current opinion in genetics & development, 2006, Volume: 16, Issue:1 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2006
[State of the art in the treatment of chronic leukemias]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2006, Volume: 47, Issue:4 Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Survival Analysis; Thiazoles; Vidarabine	2006
[New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2006, Volume: 28, Issue:8 Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2006
[Novel inhibitors of Bcr-Abl]. Postepy higieny i medycyny doswiadczalnej (Online), 2006, Volume: 60 Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Hydroxamic Acids; Imatinib Mesylate; Indoles; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Mutation; Panobinostat; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyridones; Pyrimidines; Thiazoles	2006
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Seminars in hematology, 2007, Volume: 44, Issue:1 Suppl 1 Topics: Adaptor Proteins, Signal Transducing; Aniline Compounds; Benzamides; Cancer Vaccines; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles	2007
[Molecular targeting therapy for chronic myeloid leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2007, Volume: 48, Issue:1 Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2007
What is new in chronic myeloid leukaemia? Scottish medical journal, 2007, Volume: 52, Issue:1 Topics: Antineoplastic Agents; Aurora Kinases; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Hepatomegaly; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Splenomegaly; Thiazoles	2007
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clinical colorectal cancer, 2006, Volume: 6 Suppl 1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Niacinamide; Oligonucleotides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sirolimus; Staurosporine; Sunitinib; Thiazoles	2006
[New horizon of chronic myelogenous leukemia]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Jan-28, Volume: 65 Suppl 1 Topics: Antineoplastic Agents; Benzene Derivatives; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles	2007
[Novel anti-CML agents beyond imatinib]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2007, Volume: 48, Issue:6 Topics: Adenosine Triphosphate; Aniline Compounds; Antineoplastic Agents; Benzamides; Benzene Derivatives; Binding Sites; Binding, Competitive; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles	2007
BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. The New England journal of medicine, 2007, Jul-19, Volume: 357, Issue:3 Topics: Adult; Benzamides; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2007
Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer, 2007, Sep-15, Volume: 110, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Survival Analysis; Thiazoles; Treatment Outcome	2007
[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors]. Bulletin du cancer, 2007, Volume: 94, Issue:10 Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzenesulfonates; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles	2007
Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leukemia & lymphoma, 2007, Volume: 48, Issue:12 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles	2007
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications]. Bulletin du cancer, 2008, Volume: 95, Issue:1 Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles	2008
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network : JNCCN, 2008, Volume: 6 Suppl 2 Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2008
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices. Journal of the National Comprehensive Cancer Network : JNCCN, 2008, Volume: 6 Suppl 2 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2008
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leukemia & lymphoma, 2008, Volume: 49, Issue:4 Topics: Benzamides; Dasatinib; Drug Delivery Systems; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2008
Therapy options in imatinib failures. The oncologist, 2008, Volume: 13, Issue:4 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome	2008
Management of patients with resistant or refractory chronic myelogenous leukemia. Oncology (Williston Park, N.Y.), 2008, Apr-15, Volume: 22, Issue:4 Topics: Aniline Compounds; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles; Treatment Outcome	2008
[Novel medical treatment modalities in hematology]. Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24 Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine	2008
Nilotinib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jul-01, Volume: 14, Issue:13 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Models, Chemical; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome	2008
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology (Oxford, England), 2008, Volume: 47 Suppl 5 Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Fibrosis; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Scleroderma, Systemic; Skin; Sulfonamides; Thiazoles	2008
[Management of chronic myeloid leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2008, Volume: 49, Issue:10 Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Drug Monitoring; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2008
Targeted drugs in chronic myeloid leukemia. Current medicinal chemistry, 2008, Volume: 15, Issue:29 Topics: Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins v-abl; Piperazines; Proto-Oncogene Proteins c-bcr; Pyrimidines; src-Family Kinases; Thiazoles	2008
[Chronic myeloid leukemia 2008]. Medicina clinica, 2008, Nov-15, Volume: 131, Issue:17 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dasatinib; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome	2008
Imatinib and its successors--how modern chemistry has changed drug development. Current pharmaceutical design, 2009, Volume: 15, Issue:2 Topics: Animals; Antineoplastic Agents; Aurora Kinases; Benzamides; Dasatinib; Drug Discovery; History, 20th Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Structure-Activity Relationship; Thiazoles	2009
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clinic proceedings, 2009, Volume: 84, Issue:2 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; Thiazoles; Treatment Failure	2009
Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clinical lymphoma & myeloma, 2008, Volume: 8 Suppl 3 Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2008
Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors. Clinical lymphoma & myeloma, 2008, Volume: 8 Suppl 3 Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome	2008
First-line therapy for chronic myeloid leukemia: Past, present, and future. American journal of hematology, 2009, Volume: 84, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome	2009
Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Cancer control : journal of the Moffitt Cancer Center, 2009, Volume: 16, Issue:2 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2009
Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors. Cancer control : journal of the Moffitt Cancer Center, 2009, Volume: 16, Issue:2 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2009
Treatment selection after imatinib resistance in chronic myeloid leukemia. Targeted oncology, 2009, Volume: 4, Issue:1 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Utilization; Fusion Proteins, bcr-abl; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymorphism, Genetic; Practice Guidelines as Topic; Pyrimidines; Stem Cell Transplantation; Thiazoles; Treatment Failure	2009
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Targeted oncology, 2009, Volume: 4, Issue:2 Topics: Benzamides; Cell Proliferation; Cytotoxicity, Immunologic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Pericardial Effusion; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Serositis; Thiazoles; Treatment Outcome	2009
Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia: when to change? A perspective in 2009. Current opinion in hematology, 2009, Volume: 16, Issue:2 Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2009
Response dynamics in chronic-phase chronic myeloid leukemia. Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:3 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cytogenetic Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome	2009
[Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:7 Topics: Aniline Compounds; Antineoplastic Agents; Aurora Kinases; Benzamides; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles	2009
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy? Current oncology reports, 2009, Volume: 11, Issue:5 Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome	2009
Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer treatment reviews, 2009, Volume: 35, Issue:8 Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution	2009
Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. Clinical lymphoma & myeloma, 2009, Volume: 9 Suppl 3 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome	2009
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia, 2010, Volume: 24, Issue:1 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2010
[Clinical use of tyrosine kinase inhibitors for treatment of myeloid leukemias]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:10 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Design; fms-Like Tyrosine Kinase 3; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2009
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-10, Volume: 27, Issue:35 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Drug Monitoring; Europe; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors; Transplantation, Homologous; Treatment Failure; Treatment Outcome	2009
[Clinical progress in chronic myelogenous leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:10 Topics: Benzamides; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dasatinib; Drug Discovery; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prednisolone; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome	2009
Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia & lymphoma, 2010, Volume: 51, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2010
Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors. Leukemia & lymphoma, 2009, Volume: 50 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2009
Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice. Leukemia & lymphoma, 2010, Volume: 51, Issue:3 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Comorbidity; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Mutation; Piperazines; Prognosis; Pyrimidines; src-Family Kinases; Thiazoles; Treatment Outcome	2010
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer, 2010, Mar-15, Volume: 116, Issue:6 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2010
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'. Leukemia & lymphoma, 2010, Volume: 51, Issue:4 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles; Treatment Outcome	2010
Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate. Current hematologic malignancy reports, 2006, Volume: 1, Issue:3 Topics: Algorithms; Antineoplastic Agents; Benzamides; Blast Crisis; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Combined Modality Therapy; Dasatinib; Drug Eruptions; Drug Interactions; Edema; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Thiazoles	2006
Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. Current hematologic malignancy reports, 2007, Volume: 2, Issue:2 Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Investigational; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Mice; Multicenter Studies as Topic; Mutation; Piperazines; Protein Isoforms; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles	2007
[Focus on GIST management]. Bulletin du cancer, 2010, Volume: 97, Issue:6 Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles	2010
First-line therapy for chronic myeloid leukemia: new horizons and an update. Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:3 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles	2010
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. British journal of haematology, 2010, Volume: 150, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult	2010
Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor? European journal of clinical investigation, 2010, Volume: 40, Issue:10 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2010
Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Clinical therapeutics, 2010, Volume: 32, Issue:5 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2010
[Development of ABL tyrosine kinase inhibitors]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:8 Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles	2010
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood, 2011, Feb-24, Volume: 117, Issue:8 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Interactions; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2011
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia, 2011, Volume: 25, Issue:2 Topics: Benzamides; Dasatinib; Disease Management; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2011
Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? Seminars in hematology, 2010, Volume: 47, Issue:4 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2010
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. Cancer, 2011, Feb-15, Volume: 117, Issue:4 Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Thiazoles	2011
Allosteric inhibition of BCR-ABL. Cell cycle (Georgetown, Tex.), 2010, Sep-15, Volume: 9, Issue:18 Topics: Allosteric Regulation; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2010
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer, 2011, Mar-01, Volume: 117, Issue:5 Topics: Animals; Antineoplastic Agents; Chemotherapy, Adjuvant; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome	2011
Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options. Expert review of hematology, 2010, Volume: 3, Issue:6 Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Factors; Thiazoles; Transplantation, Homologous	2010
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. Journal of hematology & oncology, 2010, Nov-26, Volume: 3 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2010
Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia. Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:6 Topics: Benzamides; Clinical Trials as Topic; Congresses as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome	2010
Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell cycle (Georgetown, Tex.), 2011, Jan-15, Volume: 10, Issue:2 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Thiazoles	2011
Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Current opinion in hematology, 2011, Volume: 18, Issue:2 Topics: Aniline Compounds; Benzamides; Clinical Trials as Topic; Dasatinib; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles	2011
[Chronic myeloid leukemia. Diagnostics, therapy and future strategy]. Der Internist, 2011, Volume: 52, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Thiazoles	2011
Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-01, Volume: 17, Issue:7 Topics: Aniline Compounds; Antineoplastic Agents; Clinical Trials as Topic; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome	2011
New drugs for chronic myelogenous leukemia. Current hematologic malignancy reports, 2011, Volume: 6, Issue:2 Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Thiazoles	2011
Pharmacotherapy for chronic myelogenous leukemia: a case-based approach. Journal of the National Comprehensive Cancer Network : JNCCN, 2011, Volume: 9 Suppl 3 Topics: Benzamides; Dasatinib; Drug Interactions; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2011
Chronic myelogenous leukemia: monitoring response to therapy. Current hematologic malignancy reports, 2011, Volume: 6, Issue:2 Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Outcome Assessment, Health Care; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles	2011
Predicting the response of CML patients to tyrosine kinase inhibitor therapy. Current hematologic malignancy reports, 2011, Volume: 6, Issue:2 Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Organic Cation Transporter 1; Piperazines; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2011
Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors. Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:2 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2011
[Indications and current development of new targeted therapies in pediatric oncology]. Bulletin du cancer, 2011, Volume: 98, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases	2011
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leukemia research, 2011, Volume: 35, Issue:9 Topics: Animals; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles	2011
Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients. Expert review of hematology, 2011, Volume: 4, Issue:3 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Cation Transport Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2011
Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia. Cancer, 2012, Jan-15, Volume: 118, Issue:2 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome	2012
[A therapeutic improvement: second generation tyrosine kinase inhibitors (TKI 2) in the treatment of chronic myelogenous leukemia]. Bulletin du cancer, 2011, Volume: 98, Issue:8 Topics: Aniline Compounds; Antineoplastic Agents; Blast Crisis; Dasatinib; Humans; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Nitriles; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles	2011
[TKI therapy for CML]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:7 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles	2011
Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib. Journal of surgical oncology, 2011, Volume: 104, Issue:8 Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Thiazoles	2011
Effects of BCR-ABL inhibitors on anti-tumor immunity. Current medicinal chemistry, 2011, Volume: 18, Issue:34 Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Dendritic Cells; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes; Thiazoles	2011
Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons. Leukemia & lymphoma, 2012, Volume: 53, Issue:7 Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2012
Tyrosine kinase inhibitors in hematological malignancies. Postepy higieny i medycyny doswiadczalnej (Online), 2011, Dec-05, Volume: 65 Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles	2011
Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib. Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:10 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome	2011
[Myeloproliferative neoplasms (including chronic myeloid leukemia)]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:1 Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Receptor, Platelet-Derived Growth Factor alpha; Thiazoles	2012
Second-generation tyrosine kinase inhibitors as first-line treatment strategy in newly diagnosed chronic phase chronic myeloid leukemia patients. Current cancer drug targets, 2012, Volume: 12, Issue:4 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles; Treatment Outcome	2012
Clinical trials in chronic myeloid leukemia. Current hematologic malignancy reports, 2012, Volume: 7, Issue:2 Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Survival Analysis; Thiazoles	2012
Chronic myelogenous leukemia for primary care physicians. Disease-a-month : DM, 2012, Volume: 58, Issue:4 Topics: Benzamides; Biopsy, Fine-Needle; Bone Marrow; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Philadelphia Chromosome; Piperazines; Platelet Count; Pregnancy; Pregnancy Complications, Neoplastic; Primary Health Care; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Translocation, Genetic	2012
[Current therapy of chronic myeloid leukemia]. Duodecim; laaketieteellinen aikakauskirja, 2012, Volume: 128, Issue:6 Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2012
Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. European journal of clinical investigation, 2012, Volume: 42, Issue:9 Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Research Design; Thiazoles; Treatment Outcome	2012
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2012, Volume: 16, Issue:22 Topics: Benzamides; Blast Crisis; Clinical Trials as Topic; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Disease Progression; Drug Resistance, Neoplasm; Health Care Costs; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Models, Economic; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles	2012
Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2012, Volume: 16, Issue:23 Topics: Antineoplastic Agents; Benzamides; Confidence Intervals; Cost-Benefit Analysis; Dasatinib; Disease Progression; Drug Resistance; Drug Therapy, Combination; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Economic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Thiazoles; Treatment Outcome; United Kingdom	2012
Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leukemia & lymphoma, 2012, Volume: 53, Issue:12 Topics: Benzamides; Dasatinib; Diarrhea; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Thrombocytopenia; Time Factors	2012
Chronic myeloid leukemia: state of the art in 2012. Current oncology reports, 2012, Volume: 14, Issue:5 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2012
[Leukemia: A highly malignant disease]. Pharmazie in unserer Zeit, 2012, Volume: 41, Issue:3 Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Disease Models, Animal; History, 19th Century; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Thiazoles; Tretinoin	2012
Evidence for therapeutic drug monitoring of targeted anticancer therapies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-10, Volume: 30, Issue:32 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Area Under Curve; Benzamides; Benzenesulfonates; Cetuximab; Dasatinib; Drug Monitoring; Everolimus; Evidence-Based Medicine; Half-Life; Humans; Imatinib Mesylate; Indoles; Injections, Intravenous; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Rituximab; Sirolimus; Sorafenib; Sunitinib; Thiazoles	2012
New and established tyrosine kinase inhibitors for chronic myeloid leukemia. Drugs of today (Barcelona, Spain : 1998), 2012, Volume: 48, Issue:9 Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles	2012
Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. American journal of hematology, 2012, Volume: 87, Issue:11 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Thiazoles; Treatment Outcome	2012
Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Health technology assessment (Winchester, England), 2012, Volume: 16, Issue:42 Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Economic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Risk Assessment; Thiazoles	2012
Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia. Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012 Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Nitriles; Piperazines; Pyrimidines; Quinolines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Outcome	2012
Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. European journal of haematology, 2013, Volume: 90, Issue:2 Topics: Dasatinib; Drug Eruptions; Exanthema; Guideline Adherence; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles	2013
The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib. Organic & biomolecular chemistry, 2013, Mar-21, Volume: 11, Issue:11 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Thiazoles	2013
Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib. Leukemia research, 2013, Volume: 37, Issue:5 Topics: Benzamides; Dasatinib; Drug Substitution; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2013
Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Pharmacotherapy, 2013, Volume: 33, Issue:8 Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles	2013
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies]. Annales de dermatologie et de venereologie, 2013, Volume: 140, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles	2013
Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. Journal of the European Academy of Dermatology and Venereology : JEADV, 2013, Volume: 27, Issue:12 Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Skin; Thiazoles	2013
Management options for refractory chronic myeloid leukemia: considerations for the elderly. Drugs & aging, 2013, Volume: 30, Issue:7 Topics: Age Factors; Aged; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013, Aug-08, Volume: 122, Issue:6 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Europe; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thiazoles; Treatment Outcome	2013
[Tyrosine kinase inhibitors - major change in the prognosis of chronic myeloid leukaemia]. Vnitrni lekarstvi, 2013, Volume: 59, Issue:7 Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Thiazoles	2013
Identifying the time to change BCR-ABL inhibitor therapy in patients with chronic myeloid leukemia. Acta haematologica, 2013, Volume: 130, Issue:4 Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome	2013
Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword? Seminars in respiratory and critical care medicine, 2013, Volume: 34, Issue:5 Topics: Apoptosis; Benzamides; Cell Proliferation; Dasatinib; Endothelial Cells; ErbB Receptors; Familial Primary Pulmonary Hypertension; Fibroblast Growth Factor 2; Fibroblasts; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Niacinamide; Phenylurea Compounds; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pulmonary Circulation; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sorafenib; src-Family Kinases; Thiazoles; Treatment Outcome; Vascular Endothelial Growth Factor A	2013
Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML). BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2014, Volume: 28, Issue:1 Topics: Antihypertensive Agents; Antineoplastic Agents; Cardiovascular Diseases; Comorbidity; Dasatinib; Diabetes Mellitus; Humans; Hypertension; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome	2014
[Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2013, Volume: 54, Issue:10 Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2013
[Current diagnostic requirements in chronic myeloid leukemia]. Wiener medizinische Wochenschrift (1946), 2013, Volume: 163, Issue:21-22 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Guideline Adherence; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Real-Time Polymerase Chain Reaction; Thiazoles; Treatment Outcome	2013
A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:6 Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Pyrimidines; Research Design; Thiazoles; Treatment Outcome	2013
Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clinical pharmacology and therapeutics, 2014, Volume: 95, Issue:3 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Dasatinib; Enzyme Inhibitors; Humans; Imatinib Mesylate; Neoplasm Proteins; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2014
Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis. Cancer treatment reviews, 2014, Volume: 40, Issue:2 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome	2014
Ever-advancing chronic myeloid leukemia treatment. International journal of clinical oncology, 2014, Volume: 19, Issue:1 Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles	2014
Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology. American Society of Hematology. Education Program, 2013, Volume: 2013 Topics: Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2013
[Chronic myeloid leukemia: up-to-date management]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:1 Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Discovery; Drug Monitoring; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Molecular Targeted Therapy; Piperazines; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2014
Treatment strategies in mastocytosis. Immunology and allergy clinics of North America, 2014, Volume: 34, Issue:2 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal, Humanized; Bone and Bones; Central Nervous System; Dasatinib; Gastrointestinal Tract; Gene Expression; Histamine Antagonists; Humans; Mast Cells; Mastocytosis; Omalizumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin; Thiazoles	2014
Tyrosine kinase inhibitors: muco-cutaneous side effects at the microscope. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2014, Volume: 149, Issue:3 Topics: Antineoplastic Agents; Benzamides; Biopsy; Dasatinib; Exanthema; Humans; Imatinib Mesylate; Microscopy, Electron; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2014
[Treatment of chronic myeloid leukemia in chronic phase]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Allografts; Benzamides; Busulfan; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Translocation, Genetic	2014
[Management of advanced stage chronic myeloid leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Disease Progression; Drug Design; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Neoplasm Staging; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles	2014
How I treat newly diagnosed chronic myeloid leukemia in 2015. American journal of hematology, 2015, Volume: 90, Issue:2 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Management; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles	2015
Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients. Annals of hematology, 2015, Volume: 94 Suppl 2 Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Disease Progression; Drug Monitoring; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Mutation; Nitriles; Prognosis; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinolines; Thiazoles	2015
Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia? Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:7 Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2015
Paediatric chronic myeloid leukaemia: Is it really a different disease? The Indian journal of medical research, 2019, Volume: 149, Issue:5 Topics: Antineoplastic Agents; Child; Cost-Benefit Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pediatrics; Pyrimidines; Thiazoles	2019

Trials

18 trial(s) available for thiazoles and s 1033

Article	Year
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood, 2007, Jan-15, Volume: 109, Issue:2 Topics: Adult; Aged; Benzamides; Cytogenetic Analysis; Dasatinib; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Treatment Outcome	2007
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood, 2008, Aug-01, Volume: 112, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cytogenetic Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Thiazoles; Treatment Failure	2008
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase Blood, 2009, May-21, Volume: 113, Issue:21 Topics: Adolescent; Adult; Aged; Benzamides; Blast Crisis; Cytogenetic Analysis; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Thiazoles; Treatment Failure; Young Adult	2009
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. Haematologica, 2009, Volume: 94, Issue:9 Topics: Adult; Aged; Benzamides; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2009
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood, 2009, Nov-12, Volume: 114, Issue:20 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Thiazoles; Young Adult	2009
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia, 2010, Volume: 24, Issue:7 Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; International Agencies; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Survival Rate; Thiazoles; Treatment Outcome; Young Adult	2010
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood, 2010, Dec-16, Volume: 116, Issue:25 Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Salvage Therapy; Thiazoles; Treatment Outcome	2010
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood, 2011, Feb-10, Volume: 117, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome; Young Adult	2011
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer, 2011, Nov-15, Volume: 117, Issue:22 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomes, Human, Pair 9; Dasatinib; Disease-Free Survival; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sequence Deletion; Thiazoles; Treatment Outcome	2011
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Current medical research and opinion, 2011, Volume: 27, Issue:6 Topics: Aged; Antineoplastic Agents; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome	2011
Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. Leukemia & lymphoma, 2012, Volume: 53, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemokines; Cytokines; Dasatinib; Female; Humans; Imatinib Mesylate; Immunophenotyping; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Subsets; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult	2012
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica, 2012, Volume: 97, Issue:7 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Piperazines; Probability; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome	2012
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood, 2012, Apr-12, Volume: 119, Issue:15 Topics: Adult; Aged; Algorithms; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Pyrimidines; Quinolines; Thiazoles; Treatment Failure; Young Adult	2012
Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance. British journal of haematology, 2013, Volume: 161, Issue:2 Topics: Animals; ATP-Binding Cassette Transporters; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transcription Factors	2013
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood, 2013, Jun-13, Volume: 121, Issue:24 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Thiazoles	2013
Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients. American journal of hematology, 2013, Volume: 88, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Retrospective Studies; Thiazoles	2013
Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. British journal of haematology, 2013, Volume: 163, Issue:5 Topics: Benzamides; Cell Cycle; Dasatinib; Drug Substitution; Drug Synergism; Follow-Up Studies; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pulse Therapy, Drug; Pyrimidines; Thiazoles; Treatment Outcome	2013
One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison. Current medical research and opinion, 2015, Volume: 31, Issue:2 Topics: Aged; Antineoplastic Agents; Dasatinib; Disease Progression; Female; Humans; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Molecular Targeted Therapy; Propensity Score; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome	2015

Other Studies

166 other study(ies) available for thiazoles and s 1033

Article	Year
Two new agents effective in Gleevec-resistant CML. Cancer biology & therapy, 2004, Volume: 3, Issue:12 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2004
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer research, 2005, Jun-01, Volume: 65, Issue:11 Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Dasatinib; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Molecular; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2005
Loss of response to imatinib: mechanisms and management. Hematology. American Society of Hematology. Education Program, 2005 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Failure	2005
Looking beyond imatinib: next line of targeted drugs for CML shows promise. JAMA, 2006, Jan-25, Volume: 295, Issue:4 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2006
Kinase inhibitors in chronic myelogenous leukemia. Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:5 Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Signal Transduction; Thiazoles	2006
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood, 2006, Oct-01, Volume: 108, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Screening Assays, Antitumor; Ethylnitrosourea; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Mutagens; Piperazines; Point Mutation; Protein Structure, Tertiary; Pyrimidines; Thiazoles	2006
Circumventing resistance to kinase-inhibitor therapy. The New England journal of medicine, 2006, Jun-15, Volume: 354, Issue:24 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2006
Tyrosine kinase inhibitors: the next generation. The Lancet. Oncology, 2006, Volume: 7, Issue:8 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2006
[Innovation of clinical trials for anti-cancer drugs in Japan--proposals from academia with special reference to the development of novel Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406 (NS-187) for imatinib-resistant chronic myelogenous leukemia]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:2 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2007
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer, 2007, Jul-15, Volume: 110, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Combined Modality Therapy; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2007
Drugs offer new hope for patients with CML who are resistant to imatinib. ONS connect, 2007, Volume: 22, Issue:7 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Interactions; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nurse's Role; Oncology Nursing; Patient Education as Topic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2007
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Aug-15, Volume: 13, Issue:16 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Sorafenib; Thiazoles	2007
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood, 2007, Dec-01, Volume: 110, Issue:12 Topics: Benzamides; Dasatinib; Discoidin Domain Receptor 1; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proteomics; Pyrimidines; Quinone Reductases; Receptor Protein-Tyrosine Kinases; Thiazoles	2007
Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy. Acta haematologica, 2007, Volume: 118, Issue:3 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Time Factors	2007
Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein. Drugs, 2007, Volume: 67, Issue:17 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Thiazoles; Transplantation, Homologous	2007
Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leukemia research, 2008, Volume: 32, Issue:6 Topics: Benzamides; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tumor Cells, Cultured	2008
Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leukemia research, 2008, Volume: 32, Issue:10 Topics: Aged; Antineoplastic Agents; Benzamides; Blood Glucose; Dasatinib; Diabetes Complications; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure	2008
Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2008, Volume: 22, Issue:7 Topics: Adult; Age of Onset; Aged; Biopsy; Cells, Cultured; Dasatinib; Fibroblasts; Humans; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Scleroderma, Systemic; Signal Transduction; Skin; Thiazoles	2008
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proceedings of the National Academy of Sciences of the United States of America, 2008, Apr-08, Volume: 105, Issue:14 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2008
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia, 2008, Volume: 22, Issue:6 Topics: Adaptor Proteins, Signal Transducing; Adult; Animals; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Cell Survival; Dasatinib; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Experimental; Male; Mice; Mice, Inbred NOD; Mice, SCID; Nuclear Proteins; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; STAT5 Transcription Factor; Thiazoles; Tumor Cells, Cultured	2008
Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. The Journal of biological chemistry, 2008, Jun-27, Volume: 283, Issue:26 Topics: Amino Acid Sequence; Antineoplastic Agents; Benzamides; Chemistry, Pharmaceutical; Dasatinib; Drug Design; Enzyme Inhibitors; Humans; Imatinib Mesylate; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Molecular Sequence Data; Piperazines; Protein Conformation; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles	2008
Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene. Journal of applied genetics, 2008, Volume: 49, Issue:2 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Point Mutation; Pyrimidines; Thiazoles; Treatment Outcome	2008
Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive Leukemia, 2009, Volume: 23, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult	2009
What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response. Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:9 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation; Thiazoles	2008
Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leukemia research, 2009, Volume: 33, Issue:2 Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis; Renal Insufficiency; Thiazoles	2009
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Molecular cancer therapeutics, 2008, Volume: 7, Issue:10 Topics: Benzamides; Bone Marrow; Cell Death; Cell Line, Tumor; Culture Media, Conditioned; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphotyrosine; Piperazines; Protein Kinase Inhibitors; Pyrimidines; RNA, Small Interfering; STAT3 Transcription Factor; Thiazoles	2008
Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. European journal of pharmacology, 2008, Dec-03, Volume: 599, Issue:1-3 Topics: Adenosine Triphosphate; Benzamides; Cell Line; Cloning, Molecular; Collagen; Dasatinib; Discoidin Domain Receptor 1; Discoidin Domain Receptors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Structural Homology, Protein; Thiazoles	2008
Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer research, 2008, Dec-01, Volume: 68, Issue:23 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; RNA, Messenger; RNA, Small Interfering; src-Family Kinases; Thiazoles; Transfection	2008
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-20, Volume: 27, Issue:3 Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nitriles; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles	2009
Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O]. Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:11 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2008
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC structural biology, 2009, Feb-24, Volume: 9 Topics: Antineoplastic Agents; Benzamides; Crystallography, X-Ray; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; NAD(P)H Dehydrogenase (Quinone); Phosphorylation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Quinone Reductases; Structure-Activity Relationship; Thiazoles	2009
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. American journal of hematology, 2009, Volume: 84, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutagenesis; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles; Treatment Failure	2009
Hydrophilic interaction liquid chromatography/tandem mass spectrometry for the simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma. Rapid communications in mass spectrometry : RCM, 2009, Volume: 23, Issue:9 Topics: Animals; Benzamides; Chromatography, Liquid; Dasatinib; Imatinib Mesylate; Linear Models; Mice; Piperazines; Pyrimidines; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazoles	2009
The toxicities of modern targeted therapies: learning from the price of progress. Targeted oncology, 2009, Volume: 4, Issue:2 Topics: Benzamides; Dasatinib; Drug Delivery Systems; ErbB Receptors; Hemorrhage; Humans; Imatinib Mesylate; Interdisciplinary Communication; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Sirolimus; Skin; Thiazoles; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2009
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. The Journal of clinical investigation, 2009, Volume: 119, Issue:5 Topics: Animals; Antineoplastic Agents; Autophagy; Benzamides; Calcium; Cell Death; Cell Line, Tumor; Chloroquine; Dasatinib; Endoplasmic Reticulum; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrolides; Mice; Mice, Inbred C3H; Microtubule-Associated Proteins; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; RNA Interference; Thiazoles; Transcription Factor CHOP; Xenograft Model Antitumor Assays	2009
Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance. Leukemia & lymphoma, 2009, Volume: 50, Issue:5 Topics: Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Thiazoles	2009
The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia. Molecular oncology, 2008, Volume: 2, Issue:3 Topics: Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Biomarkers; Dasatinib; Down-Regulation; Drug Monitoring; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Interleukin-8; Lectins, C-Type; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles	2008
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Jun-15, Volume: 877, Issue:18-19 Topics: Antineoplastic Agents; Benzamides; Calibration; Chromatography, High Pressure Liquid; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sensitivity and Specificity; Thiazoles	2009
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leukemia research, 2010, Volume: 34, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Transplantation, Homologous; Treatment Outcome; Young Adult	2010
Chronic myelogenous leukaemia market. Nature reviews. Drug discovery, 2009, Volume: 8, Issue:6 Topics: Benzamides; Dasatinib; Drug Industry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Marketing; Piperazines; Pyrimidines; Thiazoles	2009
Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation. Veterinary immunology and immunopathology, 2009, Dec-15, Volume: 132, Issue:2-4 Topics: Animals; Apoptosis; Base Sequence; Benzamides; Cat Diseases; Cats; Cell Proliferation; Dasatinib; DNA Primers; Exons; Female; Humans; Imatinib Mesylate; In Vitro Techniques; Male; Mast Cells; Mastocytosis, Systemic; Molecular Sequence Data; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Tandem Repeat Sequences; Thiazoles	2009
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood, 2009, Sep-03, Volume: 114, Issue:10 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Hospitals, Public; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Life Expectancy; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Spain; Survival Rate; Thiazoles	2009
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood, 2009, Sep-03, Volume: 114, Issue:10 Topics: Adolescent; Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Thiazoles	2009
Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Acta haematologica, 2009, Volume: 122, Issue:1 Topics: Aged; Aniline Compounds; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Stem Cell Transplantation; Thiazoles	2009
Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia. Seminars in hematology, 2009, Volume: 46, Issue:2 Suppl 3 Topics: Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2009
New directions in the treatment of imatinib failure and/or resistance. Seminars in hematology, 2009, Volume: 46, Issue:2 Suppl 3 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles	2009
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood, 2009, Oct-15, Volume: 114, Issue:16 Topics: Apoptosis; Dasatinib; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors	2009
Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activities. PLoS computational biology, 2009, Volume: 5, Issue:9 Topics: Algorithms; Benzamides; Cell Cycle; Cell Line; Cluster Analysis; Computational Biology; Dasatinib; Diphenylamine; Dose-Response Relationship, Drug; Gene Expression; Gene Expression Profiling; Humans; Imatinib Mesylate; Oligonucleotide Array Sequence Analysis; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles	2009
Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors. Hematological oncology, 2010, Volume: 28, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Republic of Korea; Salvage Therapy; Thiazoles; Treatment Outcome; Young Adult	2010
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. British journal of pharmacology, 2009, Volume: 158, Issue:4 Topics: Aniline Compounds; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cyclosporins; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Fusion Proteins, bcr-abl; Humans; Indoles; K562 Cells; Neoplasm Proteins; Neoplasms; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Substrate Specificity; Thiazoles	2009
BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure. Hong Kong medical journal = Xianggang yi xue za zhi, 2009, Volume: 15, Issue:5 Topics: Amino Acid Substitution; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome	2009
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica, 2010, Volume: 95, Issue:2 Topics: Adult; Benzamides; Cohort Studies; Cytogenetic Analysis; Dasatinib; Drug Resistance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2010
Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PloS one, 2009, Oct-20, Volume: 4, Issue:10 Topics: Antineoplastic Agents; Benzamides; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Models, Chemical; Multidrug Resistance-Associated Proteins; Neoplasms; Paclitaxel; Piperazines; Pyrimidines; Tetrazolium Salts; Thiazoles	2009
Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib. Cytotherapy, 2010, Volume: 12, Issue:1 Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Iatrogenic Disease; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Treatment Outcome	2010
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood, 2009, Dec-24, Volume: 114, Issue:27 Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome	2009
SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood, 2010, Feb-04, Volume: 115, Issue:5 Topics: Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Oligonucleotide Array Sequence Analysis; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2010
Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia, 2010, Volume: 24, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dasatinib; Drug Synergism; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2010
AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance. Chemical biology & drug design, 2010, Volume: 75, Issue:2 Topics: Adenine; Animals; Benzamides; Binding Sites; Cell Line; Computer Simulation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2010
Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment. Clinical chemistry, 2010, Volume: 56, Issue:3 Topics: Antineoplastic Agents; Clone Cells; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genotype; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2010
The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. International journal of cancer, 2010, Nov-01, Volume: 127, Issue:9 Topics: Aluminum Silicates; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cytotoxicity, Immunologic; Dasatinib; Down-Regulation; Fusion Proteins, bcr-abl; Histocompatibility Antigens Class I; Humans; Imatinib Mesylate; Interferon-gamma; K562 Cells; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles	2010
Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase. International journal of hematology, 2010, Volume: 91, Issue:3 Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Substance Withdrawal Syndrome; Thiazoles	2010
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Female; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles; Translocation, Genetic	2010
Reversible cardiotoxicity with tyrosine kinase inhibitors. Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:2 Topics: Adult; Benzamides; Cardiotoxins; Central Nervous System Neoplasms; Dasatinib; Fatal Outcome; Female; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Ventricular Dysfunction, Left	2010
Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? Swiss medical weekly, 2010, Volume: 140 Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Disease Models, Animal; Drugs, Investigational; ErbB Receptors; Fibrosis; Graft vs Host Disease; Humans; Imatinib Mesylate; Mixed Connective Tissue Disease; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pulmonary Fibrosis; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Scleroderma, Systemic; Thiazoles	2010
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:8 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cell Culture Techniques; Dasatinib; Humans; Imatinib Mesylate; K562 Cells; Mice; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2010
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer, 2010, Jun-01, Volume: 116, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome	2010
Even better kinase inhibitors for chronic myeloid leukemia. The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2010
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. Blood, 2010, Dec-23, Volume: 116, Issue:26 Topics: Benzamides; Blast Crisis; Dasatinib; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; MDS1 and EVI1 Complex Locus Protein; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogenes; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Salvage Therapy; Survival Rate; Thiazoles; Transcription Factors	2010
Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML? Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:10 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome	2010
Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid : official journal of the American Thyroid Association, 2010, Volume: 20, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland	2010
An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib. International journal of laboratory hematology, 2011, Volume: 33, Issue:2 Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Piperazines; Pyrazines; Pyrimidines; Signal Transduction; Sirolimus; Thiazoles; TOR Serine-Threonine Kinases; Up-Regulation	2011
p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells. Carcinogenesis, 2011, Volume: 32, Issue:1 Topics: Antineoplastic Agents; Benzamides; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p57; Dasatinib; Electrophoresis, Gel, Two-Dimensional; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoblotting; Immunoprecipitation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Transcription, Genetic	2011
Second-generation BCR-ABL kinase inhibitors in CML. The New England journal of medicine, 2010, 10-21, Volume: 363, Issue:17 Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Survival Rate; Thiazoles	2010
Second-generation BCR-ABL kinase inhibitors in CML. The New England journal of medicine, 2010, 10-21, Volume: 363, Issue:17 Topics: Benzamides; Dasatinib; Disease Progression; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intention to Treat Analysis; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Thiazoles	2010
Second-generation BCR-ABL kinase inhibitors in CML. The New England journal of medicine, 2010, 10-21, Volume: 363, Issue:17 Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Remission Induction; Thiazoles	2010
Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Current medical research and opinion, 2010, Volume: 26, Issue:12 Topics: Adult; Aged; Algorithms; Ambulatory Care; Antineoplastic Agents; Cohort Studies; Comorbidity; Dasatinib; Databases, Factual; Female; Health Care Costs; Health Resources; Humans; Insurance Claim Review; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Pyrimidines; Retrospective Studies; Thiazoles	2010
Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jan-15, Volume: 17, Issue:2 Topics: Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Drugs, Investigational; Fusion Proteins, bcr-abl; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Mutation; Pyridazines; Pyrimidines; Signal Transduction; Thiazoles	2011
[Chronic myeloid leukemia and targeted therapies: too many choices?]. Medecine sciences : M/S, 2010, Volume: 26, Issue:11 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Tolerance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome	2010
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica, 2011, Volume: 96, Issue:3 Topics: Antineoplastic Protocols; Benzamides; Clone Cells; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Middle Aged; Piperazines; Point Mutation; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Pyrimidines; RNA, Messenger; Thiazoles; Withholding Treatment	2011
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors. Journal of the National Cancer Institute, 2011, Feb-16, Volume: 103, Issue:4 Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine	2011
Allosteric interactions between the myristate- and ATP-site of the Abl kinase. PloS one, 2011, Jan-10, Volume: 6, Issue:1 Topics: Adenosine Triphosphate; Allosteric Regulation; Antineoplastic Agents; Binding Sites; Dasatinib; Humans; Mass Spectrometry; Myristic Acid; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles	2011
Role of Pten in leukemia stem cells. Oncotarget, 2010, Volume: 1, Issue:2 Topics: Animals; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, Tumor Suppressor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice; Neoplastic Stem Cells; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Signal Transduction; Thiazoles	2010
Nilotinib and dasatinib first-line: are we ready for imatinib replacement? Leukemia research, 2011, Volume: 35, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoadjuvant Therapy; Piperazines; Pyrimidines; Safety-Based Drug Withdrawals; Thiazoles	2011
Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia. Pharmacogenomics, 2011, Volume: 12, Issue:3 Topics: Biomarkers, Tumor; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microarray Analysis; Netherlands; Protein Kinases; Pyrimidines; Thiazoles	2011
Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time? The oncologist, 2011, Volume: 16, Issue:5 Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome	2011
Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia. European journal of haematology, 2011, Volume: 86, Issue:6 Topics: Antineoplastic Agents; Benzamides; Cross Reactions; Dasatinib; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2011
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀? The oncologist, 2011, Volume: 16, Issue:6 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2011
[KIT and KIT: from biology to clinical use]. Bulletin du cancer, 2012, Feb-01, Volume: 99, Issue:2 Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles	2012
Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. Leukemia & lymphoma, 2011, Volume: 52, Issue:11 Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Blotting, Western; Cell Line, Tumor; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Proteins; Nuclear Proteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles	2011
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Aug-10, Volume: 29, Issue:23 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medical Oncology; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Young Adult	2011
Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line. Journal of hematology & oncology, 2011, Aug-02, Volume: 4, Issue:1 Topics: Apoptosis; Dasatinib; Drug Resistance, Neoplasm; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles	2011
Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients. Leukemia, 2012, Volume: 26, Issue:1 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles	2012
The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors. Cancer immunology, immunotherapy : CII, 2012, Volume: 61, Issue:2 Topics: Antibodies, Monoclonal; Benzamides; Cells, Cultured; Dasatinib; Dendritic Cells; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunotherapy; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Membrane Glycoproteins; Molecular Targeted Therapy; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; T-Lymphocytes; Thiazoles; Up-Regulation	2012
Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response. Blood, 2011, Nov-10, Volume: 118, Issue:19 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles	2011
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib. Leukemia research, 2012, Volume: 36, Issue:1 Topics: Adult; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Pharmacological; Biomarkers, Tumor; Dasatinib; Female; Fusion Proteins, bcr-abl; Glutamic Acid; Humans; Imatinib Mesylate; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysine; Mutation, Missense; Phenylalanine; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Remission Induction; Thiazoles; Time Factors; Treatment Outcome	2012
[Roles of the 2nd generation TKIs for CML]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:10 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles	2011
Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Nov-10, Volume: 29, Issue:32 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome	2011
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). Journal of pharmaceutical and biomedical analysis, 2012, Feb-05, Volume: 59 Topics: Antineoplastic Agents; Benzamides; Calibration; Cells, Cultured; Chromatography, High Pressure Liquid; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Limit of Detection; Mass Spectrometry; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reference Standards; Reproducibility of Results; Thiazoles	2012
Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:2 Topics: Animals; Antigens, CD34; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Myeloid Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles	2012
Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model. Carcinogenesis, 2012, Volume: 33, Issue:2 Topics: Apoptosis; Aurora Kinases; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitosis; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2012
When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2011, Volume: 14, Issue:8 Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Thiazoles	2011
Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2011, Volume: 14, Issue:8 Topics: Antineoplastic Agents; Area Under Curve; Benzamides; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Models, Theoretical; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Survival Analysis; Survival Rate; Thiazoles; Time Factors; United Kingdom	2011
Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Current medical research and opinion, 2012, Volume: 28, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; International Classification of Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult	2012
Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors. Leukemia & lymphoma, 2012, Volume: 53, Issue:7 Topics: Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transcription, Genetic; Treatment Outcome; Young Adult	2012
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer cell, 2011, Dec-13, Volume: 20, Issue:6 Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Genes, ras; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyrimidines; raf Kinases; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2011
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood, 2012, Feb-23, Volume: 119, Issue:8 Topics: Aniline Compounds; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Thiazoles; Time Factors; Transcription, Genetic; Treatment Outcome	2012
AHI1 gene expression levels and BCR-ABL1 T315I mutations in chronic myeloid leukemia patients. Hematology (Amsterdam, Netherlands), 2011, Volume: 16, Issue:6 Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Time Factors; Young Adult	2011
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood, 2012, Mar-08, Volume: 119, Issue:10 Topics: Benzamides; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sequence Analysis, DNA; Thiazoles	2012
Recommendations for the management of adult chronic myeloid leukaemia in South Africa. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2011, Nov-01, Volume: 101, Issue:11 Topics: Adult; Benzamides; Comorbidity; Dasatinib; Disease Management; HIV Infections; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; South Africa; Thiazoles; Treatment Outcome	2011
NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib. The Lancet. Oncology, 2012, Volume: 13, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Delivery of Health Care; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; United Kingdom	2012
NICE backs leukaemia drug after manufacturer drops price. BMJ (Clinical research ed.), 2012, Mar-22, Volume: 344 Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Thiazoles; United Kingdom	2012
Pulmonary arterial hypertension in patients treated by dasatinib. Circulation, 2012, May-01, Volume: 125, Issue:17 Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Agents; Benzamides; Bone Morphogenetic Protein Receptors, Type II; Calcium Channel Blockers; Dasatinib; Drug Utilization; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Hemodynamics; Humans; Hydroxyurea; Hypertension, Pulmonary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Registries; Thiazoles; Treatment Outcome	2012
Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. International journal of hematology, 2012, Volume: 95, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; Female; Fusion Proteins, bcr-abl; Germany; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome; United Kingdom; United States	2012
Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PloS one, 2012, Volume: 7, Issue:4 Topics: Aniline Compounds; Benzamides; Binding Sites; Dasatinib; Drug Resistance, Neoplasm; Escherichia coli; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isomerism; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Recombinant Proteins; Spectrophotometry, Infrared; Static Electricity; Thiazoles; X-Ray Diffraction	2012
Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia. Leukemia research, 2012, Volume: 36, Issue:7 Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Choice Behavior; Dasatinib; Health Services Needs and Demand; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoadjuvant Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Research Design; Risk Assessment; Risk Factors; Thiazoles	2012
CML treatment in Asia-Pacific region. Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1 Topics: Adult; Antineoplastic Agents; Asia; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2012
Role of Src tyrosine kinases in experimental pulmonary hypertension. Arteriosclerosis, thrombosis, and vascular biology, 2012, Volume: 32, Issue:6 Topics: Animals; Apoptosis; Becaplermin; Benzamides; Cell Proliferation; Cells, Cultured; Chemotaxis; Dasatinib; Disease Models, Animal; Dose-Response Relationship, Drug; Hemodynamics; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Imatinib Mesylate; Monocrotaline; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-sis; Pyrimidines; Rats; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Thiazoles; Time Factors	2012
Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells. Cancer letters, 2012, Oct-28, Volume: 323, Issue:2 Topics: Dasatinib; Humans; K562 Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Telomerase; Thiazoles	2012
A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Current medical research and opinion, 2012, Volume: 28, Issue:7 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Patient Compliance; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles	2012
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. Haematologica, 2013, Volume: 98, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome	2013
Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2012, Aug-15, Volume: 903 Topics: Benzamides; Chromatography, High Pressure Liquid; Dasatinib; Dried Blood Spot Testing; Drug Stability; Humans; Imatinib Mesylate; Linear Models; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazoles	2012
An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents. Methods in molecular biology (Clifton, N.J.), 2012, Volume: 928 Topics: Benzamides; Cell Line; Dasatinib; Drug Discovery; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Mutation; Piperazines; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Thiazoles	2012
10 years of progress in chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network : JNCCN, 2012, Volume: 10, Issue:9 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcr; Pyrimidines; Thiazoles	2012
The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica, 2013, Volume: 98, Issue:5 Topics: Adult; Aged; Alleles; Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome	2013
[Treatment for de novo chronic myeloid leukemia in chronic phase]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 2 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2012
[Treatment of imatinib-intolerant or -resistant CML patients]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 2 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2012
Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Case-Control Studies; Dasatinib; Depression; Fatigue; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Surveys and Questionnaires; Thiazoles; United States; Young Adult	2013
BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib. British journal of haematology, 2013, Volume: 160, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Retrospective Studies; RNA, Messenger; RNA, Neoplasm; Thiazoles; Treatment Outcome	2013
Chronic myeloid leukemia: advances in diagnosis and management. JAAPA : official journal of the American Academy of Physician Assistants, 2013, Volume: 26, Issue:2 Topics: Benzamides; Dasatinib; Diagnosis, Differential; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles	2013
Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. Medicina clinica, 2013, Aug-04, Volume: 141, Issue:3 Topics: Benzamides; Blast Crisis; Clone Cells; Dasatinib; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Substitution; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Sequence Analysis, DNA; Thiazoles	2013
Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice. PloS one, 2013, Volume: 8, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome; Young Adult	2013
High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-10, Volume: 31, Issue:11 Topics: Aged; Benzamides; Dasatinib; Diagnosis, Differential; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Thiazoles; Vimentin	2013
[Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?]. Medicina clinica, 2013, Aug-04, Volume: 141, Issue:3 Topics: Benzamides; Dasatinib; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2013
[Chronic myeloid leukemia]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 8 Topics: Dasatinib; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Thiazoles	2012
Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis. Current medical research and opinion, 2013, Volume: 29, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Treatment Outcome; Young Adult	2013
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2013, May-01, Volume: 926 Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles	2013
Perforating folliculitis in a patient treated with nilotinib: a further evidence of C-kit involvement. The American Journal of dermatopathology, 2014, Volume: 36, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Eruptions; Folliculitis; Hair Follicle; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Thiazoles	2014
T315I, more or less, predicts for major molecular response: the devil is in the details! Haematologica, 2013, Volume: 98, Issue:5 Topics: Antineoplastic Agents; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Pyrimidines; Thiazoles	2013
The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia. Leukemia & lymphoma, 2014, Volume: 55, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Thiazoles; Young Adult	2014
Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations. PloS one, 2013, Volume: 8, Issue:6 Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Benzamides; Chlorocebus aethiops; COS Cells; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Molecular Docking Simulation; Mutation, Missense; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Thiazoles	2013
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. American journal of hematology, 2013, Volume: 88, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Dasatinib; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult	2013
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:17 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome	2013
Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia. Blood, 2013, Nov-07, Volume: 122, Issue:19 Topics: Benzamides; Biomarkers, Pharmacological; Cell Line, Tumor; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Statistical; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2013
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells. PloS one, 2013, Volume: 8, Issue:10 Topics: Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Heterocyclic Compounds, 2-Ring; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pteridines; Pyrazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles	2013
Pemphigus foliaceous-like reaction in a patient with chronic myeloid leukemia treated with the tyrosine kinase inhibitors nilotinib and dasatinib. International journal of dermatology, 2014, Volume: 53, Issue:4 Topics: Aged; Dasatinib; Drug Eruptions; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pemphigus; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2014
Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line. Pharmacogenetics and genomics, 2014, Volume: 24, Issue:1 Topics: Aniline Compounds; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cell Line; Cell Membrane; Dasatinib; Genetic Variation; Genotype; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Proteins; Nitriles; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles; Transduction, Genetic	2014
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome; Young Adult	2014
Development and validation of an indirect pulsed electrochemical detection method for monitoring the inhibition of Abl1 tyrosine kinase. Journal of pharmaceutical and biomedical analysis, 2014, Volume: 90 Topics: Benzamides; Calibration; Chromatography, Liquid; Dasatinib; Electrochemical Techniques; Fusion Proteins, bcr-abl; Gluconates; Imatinib Mesylate; Inhibitory Concentration 50; Limit of Detection; Linear Models; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2014
Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors. Cancer science, 2014, Volume: 105, Issue:3 Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Survival; Dasatinib; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Xenograft Model Antitumor Assays	2014
Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2015, Volume: 21, Issue:1 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles; Young Adult	2015
ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells. Oncotarget, 2014, Jan-30, Volume: 5, Issue:2 Topics: Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; Dasatinib; DNA Repair; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; K562 Cells; Mesoderm; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Thiazoles; Trans-Activators; Transcriptional Regulator ERG	2014
Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance. PloS one, 2014, Volume: 9, Issue:5 Topics: Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dasatinib; Hep G2 Cells; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Sunitinib; Thiazoles	2014
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia, 2015, Volume: 29, Issue:3 Topics: Aminosalicylic Acids; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Dasatinib; Drug Discovery; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, Reporter; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Luciferases; Molecular Docking Simulation; Neoplastic Stem Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Signal Transduction; Small Molecule Libraries; STAT3 Transcription Factor; Sulfonamides; Thiazoles	2015
ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia. International journal of hematology, 2014, Volume: 100, Issue:6 Topics: Aged; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Dasatinib; Drug Substitution; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pulmonary Alveolar Proteinosis; Pyrimidines; Thiazoles; Tomography, X-Ray Computed	2014
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. Haematologica, 2014, Volume: 99, Issue:11 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome	2014
Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. Journal of managed care & specialty pharmacy, 2014, Volume: 20, Issue:10 Topics: Adolescent; Adult; Aged; Dasatinib; Databases, Factual; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Young Adult	2014
Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs. Current medical research and opinion, 2015, Volume: 31, Issue:2 Topics: Aged; Antineoplastic Agents; Benzamides; Cohort Studies; Dasatinib; Drug Costs; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Odds Ratio; Outcome Assessment, Health Care; Patient Care; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles; United States	2015
Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea. Current medical research and opinion, 2015, Volume: 31, Issue:2 Topics: Adult; Antineoplastic Agents; Australia; Benzamides; Canada; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Therapy Management; Middle Aged; Piperazines; Practice Patterns, Physicians'; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Republic of Korea; Retrospective Studies; Thiazoles; Treatment Outcome	2015
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. American journal of hematology, 2015, Volume: 90, Issue:4 Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Agents; Benzamides; Cardiovascular Diseases; Dasatinib; Databases, Factual; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Lung Diseases; Middle Aged; Piperazines; Product Surveillance, Postmarketing; Pyrimidines; Thiazoles; United States; United States Food and Drug Administration; Young Adult	2015
Targeting Filarial Abl-like Kinases: Orally Available, Food and Drug Administration-Approved Tyrosine Kinase Inhibitors Are Microfilaricidal and Macrofilaricidal. The Journal of infectious diseases, 2015, Sep-01, Volume: 212, Issue:5 Topics: Animals; Benzamides; Brugia malayi; Dasatinib; Female; Filaricides; Imatinib Mesylate; Inhibitory Concentration 50; Larva; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2015
Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients. American journal of hematology, 2015, Volume: 90, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Substitution; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis; Thiazoles	2015
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program. American journal of hematology, 2015, Volume: 90, Issue:5 Topics: Adult; Aged; Aniline Compounds; Antineoplastic Agents; Benzamides; Compassionate Use Trials; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Retrospective Studies; Spain; Survival Analysis; Thiazoles	2015
Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography. The Kaohsiung journal of medical sciences, 2015, Volume: 31, Issue:3 Topics: Adult; Antineoplastic Agents; Dasatinib; Drug Substitution; Echocardiography; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maintenance Chemotherapy; Male; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2015
[Inhibitors for ABL, KIT and PDGFR tyrosine kinases--imatinib, nitotinib, and dasatinib]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 2 Topics: Benzamides; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Oncogene Proteins v-abl; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Thiazoles	2015
PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. Oncotarget, 2017, Apr-04, Volume: 8, Issue:14 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoenzymes; Isoquinolines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Thiazoles; Triazines	2017
Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life. Current medical research and opinion, 2021, Volume: 37, Issue:3 Topics: Antineoplastic Agents; Dasatinib; Humans; Imatinib Mesylate; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome	2021